Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 12/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436036 | 0.90 | P2RY6 (0.58) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL28293726 | 0.89 | P2RY6 (0.58) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8441389 | 0.88 | P2RY6 (0.56) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8437011 | 0.86 | P2RY6 (0.54) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8440658 | 0.86 | P2RY6 (0.54) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL4619794 | 0.85 | P2RY6 (0.55) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8439799 | 0.85 | P2RY6 (0.57) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8440615 | 0.85 | P2RY6 (0.53) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL95680 | 0.85 | P2RY6 (0.54) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8441087 | 0.84 | P2RY6 (0.59) | P2RY6P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846893-B2 | Non-ionically bound constructs, and compositions and kits comprising domains | ENZO BIOCHEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8742090-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735145-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2042606-A1 | Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use | ENZO THERAPEUTICS, INC. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080248564-A1 | Expression vector comprising ligand conjugates for use and expression of heterologus nucleotide sequences in cells | ENZO THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-0779365-B1 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS INC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080108139-A1 | Expression vector comprising nucleotide sequences coding polymerase for use in eukaryotic specific expression of functional heterologous proteins | ENZO THERAPEUTICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20030104620-A1 | Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides | ENZO BIOCHEM, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030087434-A1 | Expression vector for use gene transfer tool in genetic engineering | ENZO BIOCHEM, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20010007767-A1 | Genetic engineering | ENZO BIOCHEM, INC. | 2001-07-12 | — | — | US | disclosed |
| US-20010006816-A1 | Dna, rna hybrid | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006814-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006815-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| EP-0779365-A2 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS, INC. (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104620-A1 | Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides | HAVCR2, RNASE1, RNPEP | P2RY6 3094/4885P2RY2 3384/4885P2RY4 3304/4885 |
| US-20010006814-A1 | Chemical modification | RNASE1, DNASE1L3, DNASE1 | P2RY6 823/4885P2RY2 1495/4885P2RY4 1171/4885 |
| US-20080108139-A1 | Expression vector comprising nucleotide sequences coding polymerase for use in eukaryotic specific expression of functional heterologous proteins | RNGTT, RNASE1, MRPL21 | P2RY6 2660/4885P2RY2 3105/4885P2RY4 3450/4885 |
| US-20030087434-A1 | Expression vector for use gene transfer tool in genetic engineering | RNASE1, GUSB, DCLRE1B | P2RY6 4020/4885P2RY2 4685/4885P2RY4 4710/4885 |
| US-20010007767-A1 | Genetic engineering | DCLRE1B, RNASE1, DNASE1L3 | P2RY6 1367/4885P2RY2 2267/4885P2RY4 2337/4885 |
| US-20010006815-A1 | Chemical modification | RNASE1, DNASE1L3, DNASE1 | P2RY6 823/4885P2RY2 1495/4885P2RY4 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.